HHV-6 Reactivation and Associated Sequelae after Hematopoietic Cell Transplantation
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Human herpesvirus 6 (HHV-6) reactivation has been associated with acute graft-versus-host-disease (aGVHD), cytomegalovirus reactivation, and mortality after allogeneic hematopoietic cell transplantation (HCT), but previous studies have yielded inconsistent results. We performed a large prospective study of allogeneic HCT recipients in order to more definitively define the relationships between HHV-6 and these important outcomes. Plasma specimens were collected prospectively from 315 allogeneic HCT recipients and tested for HHV-6 DNA at baseline and twice weekly for 12 weeks. Cox proportional hazards models were used to evaluate the time-dependent associations between HHV-6 reactivation and the targeted outcomes. HHV-6 was detected in 111 of 315 patients (35%) at a median of 20 days after HCT. HHV-6 reactivation was associated with subsequent cytomegalovirus reactivation (adjusted hazard ratio [aHR], 1.9; 95% confidence interval [CI], 1.3-2.8; P = .002). High-level HHV-6 (>1,000 HHV-6 DNA copies/mL) was associated with subsequent grades II to IV aGVHD (aHR, 2.4; 95% CI, 1.60-3.6; P < .001). High-level HHV-6 reactivation was also associated with nonrelapse mortality (aHR, 2.7; 95% CI, 1.2-6.3; P = .02). HHV-6 reactivation was independently and quantitatively associated with increased risk of subsequent cytomegalovirus reactivation, aGVHD, and mortality after HCT. A randomized antiviral trial is warranted to establish causality between HHV-6 and these endpoints and to determine if reducing HHV-6 reactivation will improve outcome after HCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A population-based study of primary human herpesvirus 6 infection
Zerr, D. M., Meier, A. S., Selke, S. S., Frenkel, L. M., Huang, M.-L., Wald, A., Rhoads, M. P., Nguy, L., Bornemann, R., Morrow, R. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042207 · Cited by 462 · cited 1×
“Others have demonstrated an association between HHV-6 and rash during the first month after HCT[19-22] and HHV-6 is known to cause rash during primary acquisition.[23] Confirming the role of HHV-6 in aGVHD and distinguishing rash related to HHV-6 from rash related to aGVHD is necessary in order to target therapy appro…”
BackgroundSelf-citation
Cited by
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
“Recent studies suggest that human herpesvirus 6 is an important pathogen mainly causing complications in the central nervous system in patients with poor or delayed T-cell reconstitution, such as cord blood transplant recipients.(326) For the moment, the available antiviral drugs are not very effective in controlling…”
BackgroundPritchett, J. C., Naesens, L., & Montoya, J. (2014) · Human Herpesviruses HHV-6A, HHV-6B & HHV-7 · doi:10.1016/b978-0-444-62703-2.00019-7 · Cited by 58
Rebechi, M. T., Bork, J. T., & Riedel, D. J. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab470 · Cited by 37
Toomey, D., Phan, T. L., Nguyen, V., Phan, T. T., & Ogata, M. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13443 · Cited by 25
Li, N., Zhang, R., Wang, J., Zhu, X., Meng, F., Cao, Y., Wang, G., & Yang, Y. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1334000 · Cited by 14
Metadata
- Authors
- Zerr, D. M., Boeckh, M., Delaney, C., Martin, P. J., Xie, H., Adler, A. L., Huang, M.-L., Corey, L., & Leisenring, W. M.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 18
- Issue
- 11
- Pages
- 1700-1708
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2005401495
- Cited by
- 147
- References
- 1
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.